학력
2008.02 연세대학교 의과대학원 박사학위 취득
2000.02 연세대학교 의과대학원 석사학위 취득
1992.02 연세대학교 의과대학 졸업
1986.02 서울고등학교 졸업
경력
2015.03 ~현재 삼성서울병원 혈액종양내과 교수
2014.11 ~ 2015.02 삼성서울병원 혈액종양내과 부교수
2014.04 ~ 2014.10 아주대학병원 기획조정실장보
2007.02 ~ 2014.03 아주대학교 의과대학 조교수
2005.09 ~ 2007.01 Post-Doc fellow
2004.07 ~ 2007.01 Cancer center
2002.03 ~ 2004.06 University of Michigan
2000.03 ~ 2003.02 연세대학교 의과대학 내과학교실 혈액종양내과 전임의
1996.03 ~ 2000.02 연세대학교 신촌 세브란스병원 내과 전공의
1995.05 ~ 1996.02 연세대학교 신촌 세브란스병원 인턴
학회
2003.01 American Society of Hematology
2002.01 미국혈액학회
2000.01 대한조혈모세포이식학회
1998.01 대한혈액학회
논문
BRIT J HAEMATOL 2020 10.1111/bjh.16711
Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies
de Latour1, RP; Brodsky, RA; Ortiz, S; Risitano, AM; Jang, JH; Hillmen, P; Kulagin, AD; Kulasekararaj, AG; Rottinghaus, ST; Aguzzi, R; Gao, X; Wells, RA; Szer, J
ANTIMICROB AGENTS CH 2020 10.1128/AAC.02467-19
Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation
Maertens1, J; Logan, AC; Jang, J; Long, G; Tang, JL; Hwang, WYK; Koh, LP; Chemaly, R; Gerbitz, A; Winkler, J; Yeh, SP; Hiemenz, J; Christoph, S; Lee, DG; Wang, PN; Holler, E; Mielke, S; Akard, L; Yeo, A; Ramachandra, S; Smith, K; Pertel, P; Segal, F
ANN LAB MED 2020 10.3343/alm.2020.40.1.88
Relationship of Circulating Cytomegalovirus Levels Obtained Through Antigenemia Testing and Quantitative PCR Differs Between Children and Adults
Choi1, S; Kim, YJ; Yoo, KH; Sung, KW; Koo, HH; Kim, SJ; Jang, JH; Kim, K; Jung, CW; Huh, HJ; Kang, ES
MOL BIOL REP 2019 10.1007/s11033-019-05019-8
Anti-leukemic effects of simvastatin on NRAS(G12D) mutant acute myeloid leukemia cells
Jang1, J; Lee, J; Jang, JH; Jung, CW; Park, S
Lancet Haematol 2019 10.1016/S2352-3026(19)30153-X
Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial
Lee1, JW; Lee, SE; Jung, CW; Park, S; Keta, H; Park, SK; Kim, JA; Oh, IH; Jang, JH
ANN HEMATOL 2019 10.1007/s00277-019-03735-6
Clinical implication of renal dysfunction during the clinical course in patients with paroxysmal nocturnal hemoglobinuria: a longitudinal analysis
Kim1, JS; Cheong, JW; Mun, YC; Jang, JH; Jo, DY; Lee, JW
INT J HEMATOL 2019 10.1007/s12185-019-02699-7
Comparative study on baseline clinical characteristics of Asian versus non-Asian patients with paroxysmal nocturnal hemoglobinuria
Sakurai1, M; Jang, JH; Chou, WC; Kim, JS; Wilson, A; Nishimura, J; Chiou, TJ; Kanakura, Y; Lee, JW; Okamoto, S
BRIT J HAEMATOL 2019 10.1111/bjh.16055
Prospective randomized trial comparing two doses of rabbit anti-thymocyte globulin in patients with severe aplastic anaemia
Narita1, A; Zhu, XF; Muramatsu, H; Chen, XJ; Guo, Y; Yang, WY; Zhang, JL; Liu, F; Jang, JH; Kook, H; Kim, H; Usuki, K; Yamazaki, H; Takahashi, Y; Nakao, S; Lee, JW; Kojima, S
CLIN LYMPHOMA MYELOMA LEUK 2019 10.1016/j.clml.2019.06.003
Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System
Jung1, KS; Kim, YJ; Kim, YK; Park, SK; Kim, HG; Kim, SJ; Park, J; Choi, CW; Do, YR; Kim, I; Park, S; Mun, YC; Jeong, SH; Kim, MK; Yi, HG; Chang, MH; Kim, SY; Lee, JH; Jang, JH
ANN HEMATOL 2019 10.1007/s00277-019-03624-y
Different prognostic effects of core-binding factor positive AML with Korean AML registry data
Shin1, HJ; Min, WS; Min, YH; Cheong, JW; Lee, JH; Kim, IH; Hong, DS; Ahn, JS; Kim, HJ; Lee, WS; Jung, CW; Jang, JH; Park, Y; Kim, HJ
Lancet Haematol 2019 10.1016/S2352-3026(18)30231-X
Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study
Frey1, N; Jang, JH; Szer, J; Illes, A; Kim, HJ; Ram, R; Chong, BH; Rowe, JM; Borisenkova, E; Liesveld, J; Winer, ES; Cherfi, A; Aslanis, V; Ghaznawi, F; Strickland, S
ANN HEMATOL 2019 10.1007/s00277-018-3550-z
Utility of allogeneic hematopoietic stem cell transplantation using international donors in a homogenous ethnic population: question in the era of various alternative donors
Kim1, SA; Lee, J; Moon, JH; Lee, H; Jang, J; Cheong, JW; Youk, J; Choi, Y; Kang, M; Shin, M; Koh, Y; Shin, S
AM J HEMATOL 2019 10.1002/ajh.25334
Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry
Lee1, JW; de Latour, RP; Brodsky, RA; Jang, JH; Hill, A; Roth, A; Schrezenmeier, H; Wilson, A; Marantz, JL; Maciejewski, JP
ANN LAB MED 2018 10.3343/alm.2018.38.6.495
Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia
Kim1, HY; Lee, KO; Park, S; Jang, JH; Jung, CW; Kim, SH; Kim, HJ
BONE MARROW TRANSPL 2018 10.1038/s41409-018-0097-5
Satisfaction with sexual activity and sexual dysfunction in hematopoietic stem cell transplantation survivors and their partners: a couple study
Yoo1, KH; Kang, D; Kim, IR; Choi, EK; Kim, JS; Yoon, SS; Lee, CH; Park, S; Kim, SJ; Kim, K; Kim, WS; Jung, CW; Choi, HJ; Jang, JH; Cho, J
LEUKEMIA RES 2018 10.1016/j.leukres.2018.04.002
Which donor is better when a matched donor is not available domestically? Comparison of outcomes of allogeneic stem cell transplantation with haploidentical and international donors in a homogenous ethnic population
Park1, H; Lee, YJ; Shin, SJ; Lee, J; Park, S; Kim, I; Moon, JH; Lee, H; Jang, JH; Yoon, SS; Koh, Y
ONCOTARGET 2018 10.18632/oncotarget.23575
Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype
Ahn1, JS; Kim, HJ; Kim, YK; Lee, SS; Ahn, SY; Jung, SH; Yang, DH; Lee, JJ; Park, HJ; Lee, JY; Choi, SH; Jung, CW; Jang, JH; Kim, HJ; Moon, JH; Sohn, SK; Lee, YJ; Won, JH; Kim, SH; Zhang, ZL; Kim, T; Kim, DDH
BMC CANCER 2017 10.1186/s12885-017-3803-6
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens
Seymour1, JF; Dohner, H; Butrym, A; Wierzbowska, A; Selleslag, D; Jang, JH; Kumar, R; Cavenagh, J; Schuh, AC; Candoni, A; Recher, C; Sandhu, I; del Castillo, TB; Al-Ali, HK; Falantes, J; Stone, RM; Minden, MD; Weaver, J; Songer, S; Beach, CL; Dombret, H
J INFECT CHEMOTHER 2017 10.1016/j.jiac.2017.04.004
Atypical presentations of MERS-CoV infection in immunocompromised hosts
Kim1, SH; Ko, JH; Park, GE; Cho, SY; Ha, YE; Kang, JM; Kim, YJ; Huh, HJ; Ki, CS; Jeong, BH; Park, J; Jang, JH; Kim, WS; Kang, CI; Chung, DR; Song, JH; Peck, KR
BIOL BLOOD MARROW TR 2017 10.1016/j.bbmt.2017.06.012
Epidemiology and Risk Factors for Invasive Fungal Diseases among Allogeneic Hematopoietic Stem Cell Transplant Recipients in Korea: Results of "RISK" Study
Choi1, JK; Cho, SY; Yoon, SS; Moon, JH; Kim, SH; Lee, JH; Kim, JS; Cheong, JW; Jang, JH; Seo, BJ; Kim, YJ; Lee, HJ; Lee, J; Lee, JW; Lee, DG
Nutrition. 2017 Apr;36:67-71. doi: 10.1016/j.nut.2016.06.009. Epub 2016 Jun 25.
Patient-Generated Subjective Global Assessment as a prognosis tool in patients with multiple myeloma
Kim HS11, Lee JY2, Lim SH2, Cho J3, Kim SJ2, Jang JH2, Kim WS2, Jung CW2, Kim K4.
Oncotarget. 2017 Jan 31;8(5):8305-8314. doi: 10.18632/oncotarget.14171.
5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia
Ahn JS11,2, Kim HJ1,2, Kim YK1,2, Lee SS1, Ahn SY1, Jung SH1, Yang DH1, Lee JJ1, Park HJ2, Choi SH2, Jung CW3, Jang JH3, Kim HJ4, Moon JH5, Sohn SK5, Won JH6, Kim SH7, Michael S8, Minden MD9, Kim DD9.
J Infect. 2016 Nov;73(5):496-505. doi: 10.1016/j.jinf.2016.06.011. Epub 2016 Jul 7.
Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients
Park S11, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Chung DR2, Kang CI2, Peck KR2, Jung CW3.
Oncotarget. 2016 Sep 13;7(37):59892-59901. doi: 10.18632/oncotarget.10988.
Blood concentration of cyclosporine during early post-transplant period may have influence on the occurrence of chronic graft versus host disease in patients who received allogeneic hematopoietic stem cell transplantation
Park S11, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Jung CW1.
Ann Hematol. 2016 Aug;95(8):1223-32. doi: 10.1007/s00277-016-2691-1. Epub 2016 May 26.
Cytogenetic profiles of 2806 patients with acute myeloid leukemia-a retrospective multicenter nationwide study
Byun JM11, Kim YJ2, Yoon HJ3, Kim SY3, Kim HJ4, Yoon J4, Min YH5, Cheong JW5, Park J6, Lee JH6, Hong DS7, Park SK7, Kim HJ8, Ahn JS8, Shin HJ9, Chung JS9, Lee WS10, Lee SM10, Park Y11, Kim BS11, Lee JH12, Lee KH12, Jung CW13, Jang JH13, Min WS14, Park TS15; AML/MDS working party of Korean Society of Hematology.
J Clin Pathol. 2016 Aug;69(8):737-41. doi: 10.1136/jclinpath-2016-203649. Epub 2016 May 19.
High frequency of JAK2 exon 12 mutations in Korean patients with polycythaemia vera: novel mutations and clinical significance
Park CH11, Lee KO2, Jang JH3, Jung CW3, Kim JW1, Kim SH1, Kim HJ1.
Qual Life Res. 2016 Apr;25(4):881-90. doi: 10.1007/s11136-015-1121-5. Epub 2015 Sep 5.
Psychometric analysis of the Korean version of the high-dose chemotherapy specific quality of life questionnaire module from the European Organization for Research and Treatment of Cancer (EORTC QLQ-HDC29)
Kim KI11, Kim JH2, Ji EH3, Jang JH4, Kim JS5, Kwon JH6, Kim I7,8,9, Park S7,8,9, Velikova G10, Yoon SS11,12,13, Oh JM14,15.
Ann Hematol. 2016 Mar;95(4):625-35. doi: 10.1007/s00277-015-2580-z. Epub 2015 Dec 22.
Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML
Ahn JS11, Kim HJ2, Kim YK1, Jung SH1, Yang DH1, Lee JJ1, Kim NY3, Choi SH3, Jung CW4, Jang JH4, Kim HJ5, Moon JH6, Sohn SK6, Won JH7, Kim SH8, Kim DD9.
Future Oncol. 2016 Feb;12(3):293-302. doi: 10.2217/fon.15.326. Epub 2016 Jan 19.
Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia
Roboz GJ11, Montesinos P2, Selleslag D3, Wei A4, Jang JH5, Falantes J6, Voso MT7, Sayar H8, Porkka K9, Marlton P10, Almeida A11, Mohan S12, Ravandi F13, Garcia-Manero G13, Skikne B14, Kantarjian H13.
J Korean Med Sci. 2016 Feb;31(2):214-21. doi: 10.3346/jkms.2016.31.2.214. Epub 2016 Jan 26.
Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry
Jang JH11, Kim JS2, Yoon SS3, Lee JH4, Kim YK5, Jo DY6, Chung J7, Sohn SK8, Lee JW9.
Ann Hematol. 2016 Jan;95(2):337-44. doi: 10.1007/s00277-015-2545-2. Epub 2015 Nov 24.
Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study
Jeong SH11, Kim DY2, Jang JH3, Mun YC4, Choi CW5, Kim SH6, Kim JS7, Park JS8.
Biol Blood Marrow Transplant. 2016 Jan;22(1):61-70. doi: 10.1016/j.bbmt.2015.07.030. Epub 2015 Jul 31.
DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation
Ahn JS11, Kim HJ2, Kim YK1, Lee SS1, Jung SH1, Yang DH1, Lee JJ1, Kim NY3, Choi SH3, Jung CW4, Jang JH4, Kim HJ5, Moon JH6, Sohn SK6, Won JH7, Kim SH8, Kim DD9.
Ann Hematol. 2016 Jan;95(2):301-10. doi: 10.1007/s00277-015-2540-7. Epub 2015 Nov 4.
Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant
Ahn JS11, Kim JY1, Kim HJ2, Kim YK1, Lee SS1, Jung SH1, Yang DH1, Lee JJ1, Kim NY3, Choi SH3, Minden MD4, Jung CW5, Jang JH5, Kim HJ6, Moon JH7, Sohn SK7, Won JH8, Kim SH9, Kim DD4.
Ann Hematol. 2016 Jan;95(1):125-33. doi: 10.1007/s00277-015-2511-z. Epub 2015 Sep 29.
Distinct subgroups of paroxysmal nocturnal hemoglobinuria (PNH) with cytopenia: results from South Korean National PNH Registry
Kim JS11, Jang JH2, Yoon SS3, Lee JH4, Kim YK5, Jo DY6, Chung JS7, Sohn SK8, Lee JW9.
Ann Hematol. 2016 Jan;95(2):325-35. doi: 10.1007/s00277-015-2523-8. Epub 2015 Oct 10.
Clinical significance of bone marrow hemophagocytosis in adult patients with malignancy and non-malignancy-induced hemophagocytic lymphohistiocytosis
Lim SH11, Park S1, Jang JH1, Kim K1, Kim HJ2, Kim SH2, Kang CI3, Chung DR3, Peck KR3, Lee J4, Cha HS4, Koh EM4, Ko YH5, Kim WS1, Jung CW1, Kim SJ6,7.
Int J Hematol. 2016 Jan;103(1):44-52. doi: 10.1007/s12185-015-1889-7. Epub 2015 Oct 28.
Multicenter, prospective study to evaluate the efficacy of biweekly romiplostim administration in patients with immune thrombocytopenia
Park S11, Yoon SS2, Lee JH3, Park JS4, Jang JH5, Lee JW6.
Oncotarget. 2015 Dec 29;6(42):44985-94. doi: 10.18632/oncotarget.6242.
A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome
Jeong SH11, Kim YJ2, Lee JH3, Kim YK4, Kim SJ5, Park SK6, Do YR7, Kim I8, Mun YC9, Kim HG10, Lee WS11, Yi HG12, Joo YD13, Choi CW14, Kim SR15, Na SM15, Jang JH16.
Oncotarget. 2015 Dec 15;6(40):42803-12. doi: 10.18632/oncotarget.5658.
Iron deficient erythropoiesis might play key role in development of anemia in cancer patients
Park S11, Jung CW1, Kim K1, Kim SJ1, Kim WS1, Jang JH1.
Liver Int. 2015 Nov;35(11):2363-9. doi: 10.1111/liv.12838. Epub 2015 Apr 12.
Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy
Lee JY11, Lim SH1, Lee MY1, Kim H1, Sinn DH1, Gwak GY1, Choi MS1, Lee JH1, Jung CW1, Jang JH1, Kim WS1, Kim SJ1, Kim K1.
Lancet Haematol. 2015 Oct;2(10):e417-26. doi: 10.1016/S2352-3026(15)00149-0. Epub 2015 Oct 1.
Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial
Platzbecker U11, Wong RS2, Verma A3, Abboud C4, Araujo S5, Chiou TJ6, Feigert J7, Yeh SP8, Gotze K9, Gorin NC10, Greenberg P11, Kambhampati S12, Kim YJ13, Lee JH14, Lyons R15, Ruggeri M16, Santini V17, Cheng G18, Jang JH19, Chen CY20, Johnson B21, Bennett J22, Mannino F23, Kamel YM24, Stone N23, Dougherty S23, Chan G23, Giagounidis A25.
Transpl Infect Dis. 2015 Oct;17(5):679-87. doi: 10.1111/tid.12424. Epub 2015 Sep 26.
Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma
Park S11, Jung CW1, Jang JH1, Kim SJ1, Kim WS1, Kim K1.
Int J Hematol. 2015 Oct;102(4):401-12. doi: 10.1007/s12185-015-1862-5. Epub 2015 Sep 1.
A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes
Jang JH11, Harada H2,3, Shibayama H4, Shimazaki R5, Kim HJ6, Sawada K7, Mitani K8.
Blood Cancer J. 2015 Oct 16;5:e358. doi: 10.1038/bcj.2015.84.
Single monosomy as a relatively better survival factor in acute myeloid leukemia patients with monosomal karyotype
Jang JE11, Min YH1, Yoon J2, Kim I3, Lee JH4, Jung CW5, Shin HJ6, Lee WS7, Lee JH8, Hong DS9, Kim HJ10, Kim HJ2, Park S3, Lee KH4, Jang JH5, Chung JS6, Lee SM7, Park J8, Park SK9, Ahn JS10, Min WS2, Cheong JW1; Korean Society of Hematology AML/MDS Working Party.
Hum Immunol. 2015 Sep;76(9):636-43. doi: 10.1016/j.humimm.2015.09.009. Epub 2015 Sep 25.
KIR alloreactivity based on the receptor-ligand model is associated with improved clinical outcomes of allogeneic hematopoietic stem cell transplantation: Result of single center prospective study
Park S11, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Kang ES2, Jung CW3.
Haematologica. 2015 Sep;100(9):e351-3. doi: 10.3324/haematol.2015.126227. Epub 2015 Jun 4.
Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype
Ahn JS11, Kim HJ2, Kim YK1, Jung SH1, Yang DH1, Lee JJ1, Lee IK3, Kim NY3, Minden MD4, Jung CW5, Jang JH5, Kim HJ6, Moon JH7, Sohn SK7, Won JH8, Kim SH9, Kim N10, Yoshida K11, Ogawa S11, Kim DD4.
Blood. 2015 Jul 16;126(3):291-9. doi: 10.1182/blood-2015-01-621664. Epub 2015 May 18.
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Dombret H11, Seymour JF2, Butrym A3, Wierzbowska A4, Selleslag D5, Jang JH6, Kumar R7, Cavenagh J8, Schuh AC9, Candoni A10, Recher C11, Sandhu I12, Bernal del Castillo T13, Al-Ali HK14, Martinelli G15, Falantes J16, Noppeney R17, Stone RM18, Minden MD9, McIntyre H19, Songer S19, Lucy LM19, Beach CL19, Dohner H20.
Oncotarget. 2015 Jun 30;6(18):16653-62.
Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients
Jung HA11,2, Maeng CH3, Kim M1, Kim S1, Jung CW1, Jang JH1.
Acta Haematol. 2015;134(1):40-8. doi: 10.1159/000368711. Epub 2015 Jun 6.
Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome
Ahn JS11, Kim YK, Min YH, Cheong JW, Jang JH, Jung CW, Kim IH, Yoon HJ, Lee HG, Sohn SK, Moon JH, Kim H, Kim YJ, Won JH, Chung JS, Mun YC, Lee JH, Kim HJ.
Leuk Lymphoma. 2015 May;56(5):1550-1. doi: 10.3109/10428194.2014.971408. Epub 2014 Nov 3.
A case of CD5-positive mature B-cell neoplasm with t(10;14)(q24;q11.2) and trisomy 12
Shin SY11, Lee ST, Kim HJ, Jang JH, Jung CW, Kim SH.
Anticancer Res. 2015 May;35(5):3081-9.
Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome
Hong JY11, Seo JY2, Kim SH3, Jung HA4, Park S4, Kim K4, Jung CW4, Kim JS5, Park JS6, Kim HJ7, Jang JH8.
J Clin Oncol. 2015 Apr 10;33(11):1252-7. doi: 10.1200/JCO.2014.57.0952. Epub 2015 Mar 2.
Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia
Stone RM11, Mazzola E2, Neuberg D2, Allen SL2, Pigneux A2, Stuart RK2, Wetzler M2, Rizzieri D2, Erba HP2, Damon L2, Jang JH2, Tallman MS2, Warzocha K2, Masszi T2, Sekeres MA2, Egyed M2, Horst HA2, Selleslag D2, Solomon SR2, Venugopal P2, Lundberg AS2, Powell B2.
Ann Lab Med. 2015 Jan;35(1):159-61. doi: 10.3343/alm.2015.35.1.159. Epub 2014 Dec 8.
Two Cases of Acute Lymphoblastic Leukemia with an ela3 BCR-ABL1 Fusion Transcript
Shin SY11, Cho JH1, Kim HJ1, Jang JH2, Lee ST1, Kim SH1.
Tissue Antigens. 2014 Dec;84(6):582-3. doi: 10.1111/tan.12435. Epub 2014 Oct 10.
A new HLA-A*30 allele, A*30:81, identified by sequence-based typing
Yoon YA11, Kim JS, Yoon CE, Jang JH, Kang ES.
Vox Sang. 2014 Nov;107(4):407-15. doi: 10.1111/vox.12183. Epub 2014 Jul 31.
Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience
Lee KH11, Jung SK, Kim SJ, Jang JH, Kim K, Kim WS, Jung CW, Kim DW, Kang ES.
Leuk Lymphoma. 2014 Oct;55(10):2395-7. doi: 10.3109/10428194.2014.880429. Epub 2014 Mar 7.
Spinal cord compression in multiple myeloma: a single center experience
Jung HA11, Cho SH, Kim SJ, Jang JH, Kim WS, Jung CW, Kim K.
Anticancer Res. 2014 Aug;34(8):4299-306.
Renal Insufficiency in Newly-diagnosed Multiple Myeloma: Analysis According to International Myeloma Working Group Consensus Statement
Park S11, Han B2, Kim K3, Kim SJ1, Jang JH1, Kim WS1, Jung CW1.
Biomed Res Int. 2014;2014:437852. doi: 10.1155/2014/437852. Epub 2014 Jul 10.
Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma
Kim SM11, Kim MJ1, Jung HA1, Kim K1, Kim SJ1, Jang JH1, Kim WS1, Jung CW1.
Ann Hematol. 2014 Jun;93(6):931-5. doi: 10.1007/s00277-014-2006-3. Epub 2014 Jan 31.
Hereditary gene mutations in Korean patients with isolated erythrocytosis
Jang JH11, Seo JY, Jang J, Jung CW, Lee KO, Kim SH, Kim HJ.
Acta Haematol. 2014;131(4):193-9. doi: 10.1159/000354839. Epub 2013 Nov 26.
Positive Correlation between Baseline PET or PET/CT Findings and Clinical Parameters in Multiple Myeloma Patients
Park S11, Lee SJ, Chang WJ, Maeng CH, Hong JY, Choi MK, Kim YS, Jung CW, Jang JH, Kim SJ, Kim WS, Choi JY, Kim K.
Int J Hematol. 2014;99(5):635-43. doi: 10.1007/s12185-014-1549-3. Epub 2014 Mar 20.
Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes
Kim Y11, Kim IH, Kim HJ, Park S, Lee KH, Kim SJ, Lee JH, Kim DY, Yoon SS, Kim YK, Jang JH, Park SY, Ahn JS, Cheong CW, Lee JH, Cheong JW; Korean Society of Hematology Acute myeloid Leukemia/Myelodysplastic Syndrome Working Party.
Ann Hematol.?2014 Apr;93(4):603-8. doi: 10.1007/s00277-013-1915-x. Epub 2013 Oct 19.
Clinical significance of SF3B1 mutations in Korean patients with myelodysplastic syndromes and myelodysplasia/myeloproliferative neoplasms with ring sideroblasts
Seo JY11,?Lee KO,?Kim SH,?Kim K,?Jung CW,?Jang JH,?Kim HJ.
Anticancer Res. 2014 Feb;34(2):1037-45.
Prognostic Factor Analysis in Core-Binding Factor-positive Acute Myeloid Leukemia
Jung HA11, Maeng CH, Park S, Kim SJ, Kim K, Jang JH, Jung CW.
Ann Hematol. 2014 Jan;93(1):99-105. doi: 10.1007/s00277-013-1952-5. Epub 2013 Nov 16.
DCEP for relapsed or refractory multiple myeloma after therapy with novel agents
Park S11, Lee SJ, Jung CW, Jang JH, Kim SJ, Kim WS, Kim K.
J Korean Med Sci. 2014 Jan;29(1):61-8. doi: 10.3346/jkms.2014.29.1.61. Epub 2013 Dec 26.
Success Rate and Risk Factors for Failure of Empirical Antifungal Therapy with Itraconazole in Patients with Hematological Malignancies: A Multicenter, Prospective, Open-Label, Observational Study in Korea
Kim SJ11, Cheong JW1, Min YH1, Choi YJ2, Lee DG3, Lee JH4, Yang DH5, Lee SM6, Kim SH7, Kim YS8, Kwak JY9, Park J10, Kim JY11, Kim HG12, Kim BS13, Ryoo HM14, Jang JH15, Kim MK16, Kang HJ17, Cho IS18, Mun YC19, Jo DY20, Kim HY21, Park BB22, Kim JS1.
J?Korean?Med Sci.?2013 Nov;28(11):1563-72. doi: 10.3346/jkms.2013.28.11.1563. Epub 2013 Oct 31.
Korean Guideline for Iron Chelation Therapy in Transfusion-Induced Iron Overload
Jang JH11,?Lee JH,?Yoon SS,?Jo DY,?Kim HJ,?Chung J,?Lee JW;?Korean?Society of Hematology Aplastic Anemia Working Party.
Int J Hematol.?2013 Jun;97(6):749-57. doi: 10.1007/s12185-013-1346-4. Epub 2013 May 1.
Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry
Lee JW11,?Jang JH,?Kim JS,?Yoon SS,?Lee JH,?Kim YK,?Jo DY,?Chung J,?Sohn SK.
Am J Hematol. 2012 Jan;87(1):37-41. doi: 10.1002/ajh.22193. Epub 2011 Nov 25.
Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity
Ahn HK11, Jang JH, Kim K, Kim HJ, Kim SH, Jung CW, Kim DH.
Haematologica.?2011 Oct;96(10):1441-7. doi: 10.3324/haematol.2011.046078. Epub 2011 Jun 9.
A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome
Lee JH11,?Jang JH,?Park J,?Park S,?Joo YD,?Kim YK,?Kim HG,?Choi CW,?Kim SH,?Park SK,?Park E,?Min YH.
Clin Lymphoma Myeloma Leuk.?2011 Jun;11(3):273-9. doi: 10.1016/j.clml.2011.03.015. Epub 2011 Apr 20.
External Validation of Newly Proposed Cytogenetic Risk Classification in Patients Who Have Myelodysplastic Syndrome: A Retrospective Analysis at a Single Institution
Yun J11,?Kim DH,?Kong JH,?Kim HJ,?Kim SH,?Kim K,?Jang JH,?Jung CW.
Transplant Proc.?2010 Nov;42(9):3723-8. doi: 10.1016/j.transproceed.2010.09.005.
Feasibility of Second Hematopoietic Stem Cell Transplantation Using Reduced-Intensity Conditioning with Fludarabine and Melphalan after a Failed Autologous Hematopoietic Stem Cell Transplantation
Hong JY11,?Choi MK,?Kim DH,?Kim SJ,?Kim K,?Kim WS,?Chung CW,?Kim HO,?Min YH,?Jang JH.
Leuk Lymphoma.?2010 Dec;51(12):2250-7. doi: 10.3109/10428194.2010.524324. Epub 2010 Oct 7.
Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience
Iastrebner M11,?Jang JH,?Nucifora E,?Kim K,?Sackmann F,?Kim DH,?Orlando S,?Jung CW,?Basquiera A,?Klein G,?Santini F,?Bernard HI,?Korin J,?Taborda G.
Acta Haematol.?2010;124(2):92-7. doi: 10.1159/000315558. Epub 2010 Jul 21.
Efficacy and Safety of Micafungin as an Empirical Antifungal Agent for Febrile Neutropenic Patients with Hematological Diseases
Park JS11,?Kim DH,?Choi CW,?Jeong SH,?Choi JH,?Kim K,?Kim SJ,?Jung CW,?Yang DH,?Jang JH.
Int J Hematol. 2010 Jun;91(5):886-91. doi: 10.1007/s12185-010-0580-2. Epub 2010 May 8.
A randomized trial of preemptive therapy for prevention of cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation
Kim ST11, Lee MH, Kim SY, Kim SJ, Kim DH, Jang JH, Kim K, Kim WS, Jung CW.
J Clin Oncol. 2010 Feb 1;28(4):e54-5. doi: 10.1200/JCO.2009.23.7560. Epub 2009 Nov 16.
Gastric Recurrence of Extramedullary Granulocytic Sarcoma After Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
Choi ER11, Ko YH, Kim SJ, Jang JH, Kim K, Kang WK, Jung CW, Kim DH.
Leuk Res. 2010 Feb;34(2):166-72. doi: 10.1016/j.leukres.2009.05.009. Epub 2009 Jun 10.
BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients
Moon JH11, Sohn SK, Lee MH, Jang JH, Kim K, Jung CW, Kim DH.
Eur J Haematol.?2008 Nov;81(5):364-73. doi: 10.1111/j.1600-0609.2008.01124.x. Epub 2008 Jul 10.
Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS
Park MJ11,?Kim HJ,?Kim SH,?Kim DH,?Kim SJ,?Jang JH,?Kim K,?Kim WS,?Jung CW.
동병원 동일과 LIST
유방암
월요일오전 월요일오후
수요일오전
수요일오후
목요일오후
백혈병,만성골수증식성질환,조혈모세포이식,출혈질환
위암,대장암,취담도암,희귀부인암
화요일오전
화요일오후
수요일오후
목요일오후
금요일오전
금요일오후
토요일오전
위암,대장암,육종,간담췌암
수요일오전
수요일오후
목요일오후
금요일오후
토요일오전
유방암,원발부위불명암
월요일오전
화요일오전
화요일오후
목요일오전
금요일오후
타병원 동일과 LIST
서울대학교병원
종양,항암화학요법,대장암,간암,유방암
서울아산병원
골수이식,골수구성백혈병,재생불량성빈혈
가톨릭대학교 서울성모병원
림프종,면역세포치료,조혈모세포이식
서울대학교병원
림프종,폐암,두경부암,흑색종,전이암
건국대학교병원
백혈병,빈혈,림프종,골수종,조혈모세세포이식
신촌세브란스 어린이병원
선천성기형,희귀질환,대사질환,유전자검사
중앙대학교병원
위암,대장암,두경부암,식도암,항암치료
|
|